Arsenic compounds: The wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology
- 4 May 2021
- journal article
- review article
- Published by Elsevier BV in European Journal of Medicinal Chemistry
- Vol. 221, 113519
- https://doi.org/10.1016/j.ejmech.2021.113519
Abstract
No abstract availableKeywords
Funding Information
- National Major Science and Technology Projects of China
- Beijing Natural Science Foundation
This publication has 117 references indexed in Scilit:
- Microbial synthesis of poly-3-hydroxybutyrate and its application as targeted drug delivery vehicleBioresource Technology, 2013
- Requirement of PML SUMO Interacting Motif for RNF4- or Arsenic Trioxide-Induced Degradation of Nuclear PML IsoformsPLOS ONE, 2012
- Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cellsInternational Journal of Oncology, 2011
- Mitochondrial Peroxiredoxin III is a Potential Target for Cancer TherapyInternational Journal of Molecular Sciences, 2011
- Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell linesInternational Journal of Nanomedicine, 2011
- Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview)Toxins, 2010
- Mineral Arsenicals in Traditional Medicines: Orpiment, Realgar, and ArsenoliteThe Journal of pharmacology and experimental therapeutics, 2008
- Dissection of mechanisms of Chinese medicinal formula Realgar- Indigo naturalis as an effective treatment for promyelocytic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2008
- Retinoic Acid and Arsenic for Treating Acute Promyelocytic LeukemiaPLoS Medicine, 2005
- Induction of DNA damage by dimethylarsine, a metabolite of inorganic arsenics, is for the major part likely due to its peroxyl radicalBiochemical and Biophysical Research Communications, 1990